Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Price Tags, Economics Driving M&A Will Endure In ’08, Biotech Investors Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Recession indicators are giving health care investors the jitters but fund managers at BIO CEO & Investor Conference remain confident on biotech.

You may also be interested in...



Despite Strategic Review, Biogen Idec To Remain Independent

The biotech has not received “any definitive offers.”

AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune

Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.

Regeneron Leaders On Getting A Call From Trump And Building A Bioreactor Farm

Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel